stars 1 stars 2 stars 3

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-clinical through to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with a large exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. Find out more about our current vacancies at: https://polypeptide.teamtailor.com/

PolyPeptide Group Questions

The PolyPeptide Group annual revenue was $300 million in 2026.

Stéphane Varray is the Chief Commercial Officer (CCO) of PolyPeptide Group.

1,065 people are employed at PolyPeptide Group.

PolyPeptide Group is based in Zug, Zug.

The NAICS codes for PolyPeptide Group are [541, 3254, 54, 325414, 5417, 325, 541711, 32, 32541, 54171].

The SIC codes for PolyPeptide Group are [28, 283].

Top PolyPeptide Group Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users